home / stock / nktx / nktx quote
Last: | $6.47 |
---|---|
Change Percent: | -1.45% |
Open: | $6.3 |
Close: | $6.47 |
High: | $6.53 |
Low: | $6.08 |
Volume: | 583,691 |
Last Trade Date Time: | 07/22/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$6.47 | $6.3 | $6.47 | $6.53 | $6.08 | 583,691 | 07-22-2024 |
$6.21 | $6.68 | $6.21 | $6.68 | $6.135 | 745,859 | 07-19-2024 |
$6.65 | $7.54 | $6.65 | $7.55 | $6.33 | 1,058,046 | 07-18-2024 |
$7.57 | $7.74 | $7.57 | $8 | $7.46 | 940,140 | 07-17-2024 |
$8 | $7.28 | $8 | $8.23 | $7.05 | 2,774,039 | 07-16-2024 |
$7.02 | $6.56 | $7.02 | $7.24 | $6.53 | 972,528 | 07-15-2024 |
$6.51 | $6.68 | $6.51 | $6.97 | $6.4 | 1,008,355 | 07-12-2024 |
$6.465 | $5.56 | $6.465 | $6.56 | $5.56 | 1,031,832 | 07-11-2024 |
$5.48 | $5.72 | $5.48 | $5.74 | $5.4 | 510,043 | 07-10-2024 |
$5.72 | $5.28 | $5.72 | $5.73 | $5.16 | 623,645 | 07-09-2024 |
$5.3 | $5.27 | $5.3 | $5.48 | $5.16 | 567,452 | 07-08-2024 |
$5.18 | $5.33 | $5.18 | $5.34 | $5.115 | 361,699 | 07-05-2024 |
$5.355 | $5.26 | $5.355 | $5.5866 | $5.14 | 232,697 | 07-04-2024 |
$5.355 | $5.26 | $5.355 | $5.5866 | $5.14 | 232,697 | 07-03-2024 |
$5.26 | $5.78 | $5.26 | $5.89 | $5.245 | 564,510 | 07-02-2024 |
$5.85 | $5.9 | $5.85 | $6.11 | $5.78 | 608,759 | 07-01-2024 |
$5.91 | $5.91 | $5.91 | $5.96 | $5.63 | 4,008,557 | 06-28-2024 |
$5.86 | $5.97 | $5.86 | $6.12 | $5.63 | 882,364 | 06-27-2024 |
$5.97 | $6.09 | $5.97 | $6.09 | $5.74 | 988,767 | 06-26-2024 |
$6.13 | $5.57 | $6.13 | $6.15 | $5.52 | 950,342 | 06-25-2024 |
News, Short Squeeze, Breakout and More Instantly...
SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced changes to its leadership team. Nadir Mahmood, Ph.D., will join Nkarta as President this month, sharing...
Patient screening underway in Ntrust-1, the first U.S.-based clinical trial of an engineered NK cell therapy for the treatment of lupus nephritis IND cleared for Ntrust-2, a clinical trial for NKX019 for the treatment of systemic sclerosis, myositis and vasculitis Clinical data ...